Study |
Time |
Treatment |
Outcome (scale) |
N of Pts |
Baseline Mean |
End of Study Mean |
Absolute Benefit |
Relative Difference |
Altman 1998 |
1‐4 wk |
E: Hyalgan |
Pain after walking 50 feet (0‐100 mm VAS) |
163 |
54 |
25 |
1 (W) |
1.8% (W) |
|
|
C: Saline |
|
167 |
55 |
25 |
|
|
Altman 1998 |
5‐13 wk |
E: Hyalgan |
Pain after walking 50 feet (0‐100 mm VAS) |
163 |
54 |
23 |
0 |
0 |
|
|
C: Saline |
|
167 |
55 |
24 |
|
|
Altman 1998 |
14‐26 wk |
E: Hyalgan |
Pain after walking 50 feet (0‐100 mm VAS) |
163 |
54 |
18 |
‐2 (I) |
‐3.6% (I) |
|
|
C: Saline |
|
167 |
55 |
21 |
|
|
Dougados 1993 |
1‐4 wk |
E: Hyalectin |
Pain on movement (0‐100 mm VAS) |
52 |
67.85 |
34.13 |
‐7.52 (I) |
‐12.16% (I) |
|
|
C: Saline |
|
50 |
61.82 |
35.62 |
|
|
Dougados 1993 |
45‐52 wk |
E: Hyalectin |
Pain on movement (0‐100 mm VAS) |
47 |
67.85 |
28.51 |
‐6.87(I) |
‐11.11% (I) |
|
|
C: Saline |
|
48 |
61.82 |
29.35 |
|
|
Carrabba 1995 |
1‐4 wk |
E: Hyalgan (5) |
Pain at rest (0‐100 mm VAS) |
20 |
43.6 |
28.3 |
‐7.1 (I) |
‐15.6% (I) |
|
|
C: Saline |
|
20 |
45.6 |
37.4 |
|
|
Carrabba 1995a |
1‐4 wk |
E: Hyalgan (3) |
Pain at rest (0‐100 mm VAS) |
20 |
44.7 |
30.3 |
‐6.2 (I) |
‐13.6% (I) |
|
|
C: Saline |
|
20 |
45.6 |
37.4 |
|
|
Carrabba 1995b |
1‐4 wk |
E: Hyalgan (5) |
Pain at rest (0‐100 mm VAS) |
20 |
43.6 |
28.3 |
‐12.4 (I) |
‐28.6% (I) |
|
|
C: Arthrocentesis |
|
20 |
43.3 |
40.4 |
|
|
Carrabba 1995c |
1‐4 wk |
E: Hyalgan (3) |
Pain at rest (0‐100 mm VAS) |
20 |
44.7 |
30.3 |
‐11.5 (I) |
‐26.6% (I) |
|
|
C: Arthrocentesis |
|
20 |
43.3 |
40.4 |
|
|
Corrado 1995 |
1‐4 wk |
E: Hyalgan |
Pain at rest (0‐100 mm VAS) |
19 |
22.5 |
9.4 |
‐8.5 (I) |
‐62% (I) |
|
|
C: Saline |
|
16 |
13.7 |
9.1 |
|
|
Dougados 1993 |
1‐4 wk |
E: Hyalectin |
Pain at rest (0‐100 mm VAS) |
52 |
31.44 |
10.87 |
‐7.72 (I) |
‐28.03% (I) |
|
|
C: Saline |
|
48 |
27.54 |
14.69 |
|
|
Henderson 1994 |
1‐4 wk |
E: Hyalgan |
Pain at rest (0‐100 mm VAS) |
18 |
20.8 |
17.7 |
‐4.1 (I) |
‐13.5% (I) |
|
|
C: Saline |
|
19 |
30.3 |
31.3 |
|
|
Henderson 1994a |
1‐4 wk |
E: Hyalgan |
Pain at rest (0‐100 mm VAS) |
22 |
25.2 |
25.3 |
15 (W) |
38.5% (W) |
|
|
C: Saline |
|
25 |
38.9 |
24.0 |
|
|
Carrabba 1995 |
5‐13 wk |
E: Hyalgan (5) |
Pain at rest (0‐100 mm VAS) |
20 |
43.6 |
29.3 |
‐8.6 (I) |
‐18.9% (I) |
|
|
C: Saline |
|
20 |
45.6 |
39.9 |
|
|
Carrabba 1995a |
5‐13 wk |
E: Hyalgan (3) |
Pain at rest (0‐100 mm VAS) |
20 |
44.7 |
33.0 |
‐6 (I) |
‐13.2% (I) |
|
|
C: Saline |
|
20 |
45.6 |
39.9 |
|
|
Carrabba 1995b |
5‐13 wk |
E: Hyalgan (5) |
Pain at rest (0‐100 mm VAS) |
20 |
43.6 |
29.3 |
‐14.2 (I) |
‐32.8% (I) |
|
|
C: Arthrocentesis |
|
20 |
43.3 |
43.2 |
|
|
Carrabba 1995c |
5‐13 wk |
E: Hyalgan (3) |
Pain at rest (0‐100 mm VAS) |
20 |
44.7 |
33.0 |
‐11.6 (I) |
‐26.8% (I) |
|
|
C: Arthrocentesis |
|
20 |
43.3 |
43.2 |
|
|
Corrado 1995 |
5‐13 wk |
E: Hyalgan |
Pain at rest (0‐100 mm VAS) |
19 |
22.5 |
5.1 |
‐15.9 (I) |
‐116.1% (I) |
|
|
C: Saline |
|
16 |
13.7 |
12.2 |
|
|
Dougados 1993 |
45‐52 wk |
E: Hyalectin |
Pain at rest (0‐100 mm VAS) |
47 |
31.44 |
11.87 |
‐1.68 (I) |
‐6.10% (I) |
|
|
C: Saline |
|
48 |
27.54 |
9.65 |
|
|
Henderson 1994 |
1‐4 wk |
E: Hyalgan |
Pain at night (0‐100 mm VAS) |
18 |
69.6 |
45.50 |
‐10.3 (I) |
‐15.1% (I) |
|
|
C: Saline |
|
19 |
68.0 |
54.20 |
|
|
Henderson 1994a |
1‐4 wk |
E: Hyalgan |
Pain at night (0‐100 mm VAS) |
22 |
68.3 |
60.20 |
4.4 (W) |
6% (W) |
|
|
C: Saline |
|
25 |
73.3 |
60.80 |
|
|
Corrado 1995 |
1‐4 wk |
E: Hyalgan |
Flexion (degrees) |
19 |
114.7 |
123.5 |
2.1 (I) |
1.9% (I) |
|
|
C: Saline |
|
16 |
113.3 |
120.0 |
|
|
Corrado 1995 |
5‐13 wk |
E: Hyalgan |
Flexion (degrees) |
19 |
114.7 |
125.5 |
6.2 (I) |
5.5% (I) |
|
|
C: Saline |
|
16 |
113.3 |
117.9 |
|
|
Corrado 1995 |
1‐4 wk |
E: Hyalgan |
Synovial fluid volume (ml) |
21 |
20.3 |
14.10 |
‐2.3 (I) |
‐15% (I) |
|
|
C: Saline |
|
19 |
15.3 |
11.40 |
|
|
Dougados 1993 |
1‐4 wk |
E: Hyalectin |
Synovial fluid volume (ml) |
55 |
18.5 |
6.10 |
‐6.4 (I) |
‐46% (I) |
|
|
C: Saline |
|
55 |
13.9 |
7.90 |
|
|
Corrado 1995 |
5‐13 wk |
E: Hyalgan |
Synovial fluid volume (ml) |
21 |
20.3 |
2.30 |
‐13.1 (I) |
‐85.6% (I) |
|
|
C: Saline |
|
19 |
15.3 |
10.40 |
|
|
Jubb 2001a |
45‐52 wk |
E: Hyalgan |
Joint space width (mm) |
136 |
4.9 |
4.80 |
0 |
0 |
|
|
C: Saline |
|
137 |
4.5 |
4.40 |
|
|
Jubb 2001b |
45‐52 wk |
E: Hyalgan |
Joint space width (mm) |
76 |
5.9 |
5.80 |
0.4 (I) |
6.8% (I) |
|
|
C: Saline |
|
63 |
5.9 |
5.40 |
|
|
Jubb 2001c |
45‐52 wk |
E: Hyalgan |
Joint space width (mm) |
60 |
3.5 |
3.50 |
‐0.2 (W) |
‐5.9% (W) |
|
|
C: Saline |
|
74 |
3.4 |
3.60 |
|
|
St. J. Dixon 1988 |
1‐4 wk |
E: Hyalgan |
Pain on movement (0‐100 mm VAS) |
28 |
66.52 |
50.54 |
‐14.13 (I) |
‐21.17% (I) |
|
|
C: Vehicle |
|
33 |
66.76 |
64.91 |
|
|
St. J. Dixon 1988 |
45‐52 wk (repeat) |
E: Hyalgan |
Pain on movement (0‐100 mm VAS) |
11 |
66.52 |
48.45 |
‐8.31(I) |
‐12.45% (I) |
|
|
C: Vehicle |
|
13 |
66.76 |
57.00 |
|
|
St. J. Dixon 1988 |
1‐4 wk |
E: Hyalgan |
Pain at rest (0‐100 mm VAS) |
29 |
30.86 |
20.50 |
‐11.61 (I) |
‐54.28% (I) |
|
|
C: Vehicle |
|
33 |
21.39 |
22.64 |
|
|
St. J. Dixon 1988 |
45‐52 wk (repeat) |
E: Hyalgan |
Pain at rest (0‐100 mm VAS) |
11 |
30.86 |
25.36 |
‐4.97 (I) |
‐23.24% (I) |
|
|
C: Vehicle |
|
14 |
21.39 |
20.86 |
|
|